News

HealthShots on MSN3d
2025 ACMG Recap: BioLogic Pharma Solutions Presents Discovery on Rare Disease Patient Identification Using Advanced Genetic Analytics
Genetic specialists from across the globe gathered in the halls of the Los Angeles Convention Center last month for the 2025 ...
Nasdaq1mon
NeuroNOS Receives FDA Orphan Drug Designation for BA-102 to Treat Phelan-McDermid Syndrome
The FDA has granted Orphan Drug Designation to NeuroNOS's BA-102 for treating Phelan-McDermid Syndrome, initiating trials in 2026. NeuroNOS, a subsidiary of Beyond Air, has received Orphan Drug ...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug ...
Mena FN1mon
Neuronos Granted FDA Orphan Drug Designation For Phelan-Mcdermid Syndrome, A Neurodevelopmental Disorder Linked To Autism
“By focusing on the genetic underpinnings of Phelan-McDermid Syndrome-a syndromic form of autism-we aim to address the root cause of symptoms and offer new hope where few options currently exist.
BioWorld1mon
FDA grants orphan drug designation to BA-102 for Phelan-McDermid syndrome
FDA grants orphan drug designation to BA-102 for Phelan-McDermid syndrome April 22, 2025 Neuronos Ltd., a subsidiary of Beyond Air Inc., has announced BA-102 has been awarded U.S. orphan drug ...
Finanznachrichten1mon
Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
"By focusing on the genetic underpinnings of Phelan-McDermid Syndrome-a syndromic form of autism-we aim to address the root cause of symptoms and offer new hope where few options currently exist." ...